Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2025

Firm announcement – No. 9 / 2025

Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Administrators, Corporate Management and employees for 2025

Copenhagen, Denmark, April 19, 2025 – Zealand Pharma A/S (“the Firm” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology firm targeted on the invention and improvement of revolutionary peptide-based medicines, pronounces the implementation of long-term incentive programs for 2025 (the “LTIP”) for Zealand Pharma’s Board of Administrators, Corporate Management and employees in accordance with Zealand Pharma’s remuneration coverage and total tips for incentive pay, as adopted on the annual normal assembly held on March 20, 2024 (“Remuneration Coverage”).

Lengthy-term incentive program

Zealand Pharma has made the next awards in its long-term incentive plan. It has awarded:

• 29,169 restricted share models (“RSUs”) to Zealand Pharma’s Board of Administrators
• 96,788 efficiency share models (“PSUs”) and 96,788 RSUs have been awarded to Zealand Pharma’s Corporate Management
• 18,502 RSUs have been awarded to Zealand Pharma’s US employees and
• 128,519 RSU’s have been awarded to Zealand Pharma’s employees in Denmark (besides for members of Corporate Management).

Zealand Pharma applied the LTIP to align with chosen European and U.S. biotech friends, and it’s meant to drive long-term efficiency, align the Corporate Management’s and employees’ pursuits with these of Zealand Pharma’s shareholders, and help the attraction, retention and motivation of first-rate expertise.

The quantity of granted RSUs and PSUs could also be adjusted as a consequence of e.g., adjustments in Zealand Pharma’s share capital construction or different vital occasions, topic to acquiring a calculation made by Zealand Pharma’s auditor or an impartial third celebration.

Board RSUs

To the extent that the Board member holds any further position as member of Zealand Pharma’s Audit Committee, Remuneration Committee and/or Scientific Committee, the Board member has acquired a further grant of RSUs in accordance with the Remuneration Coverage. Such grants are included within the above-mentioned complete quantity.

As regards to the 2025 RSU grants to the Board of Administrators, RSUs will vest yearly on the annual normal assembly (AGM) in equal tranches over three years (from April 19, 2025 to AGM 2028).

For any given monetary 12 months, the entire quantity of RSUs granted to any member of the Board of Administrators can’t exceed 8,000 RSUs, and on the time of grant the entire worth of RSUs granted to the Chair of the Board can’t exceed an quantity of DKK 3 million. For Board members serving on a committee (aside from the Chair of the Board), the entire worth can’t exceed DKK 1.5 million and for different Board members not serving on a committee, the entire worth can’t exceed DKK 600,000. Every vested RSU entitles the holder to obtain one share in Zealand Pharma for gratis topic to sure circumstances that embody the Board member’s continued service on the Board of Administrators (or Board Committee the place related) for the complete time period of being elected.

The members of the Board of Administrators are additionally topic to a holding requirement to be met inside a interval of two years from the time the Board member was first elected in the event that they proceed to be members of the Board of Administrators. That is to align the pursuits of the Board of Administrators and the shareholders. The holding requirement for the members in query quantities to 200% of their annual RSU grant worth, as decided on the grant date.
The grant of RSUs for the members of the Board of Administrators below this program may have an estimated truthful market worth of DKK 12.4 million, based mostly on every RSU having a good market worth of DKK 424.50.

The truthful market worth of the RSUs is set because the closing worth of Zealand Pharma’s shares on Nasdaq Copenhagen A/S the buying and selling day previous to the grant.

Corporate Management RSUs and PSUs

Members of the Corporate Management are eligible to obtain an annual grant of PSUs and RSUs.
The PSU ingredient of the award is free of cost topic to achievement of sure predefined efficiency targets. Consequently, the PSUs vest based mostly upon sure pre-defined market-based objectives that encourage share efficiency towards comparable firms (equivalent to complete shareholder return efficiency towards Nasdaq Biotechnology Index).

Relying on the extent of achievement of the objectives, the PSUs might vest between 0% and 150% after three years (on April 19, 2028). As regards to the 2025 RSU grants to Zealand Pharma’s Corporate Management, RSUs will vest yearly in equal tranches over three years (from April 19, 2025, to April 19, 2028). Every vested RSU entitles the holder to obtain one share in Zealand Pharma for gratis and topic to sure circumstances that embody the holder’s continued employment at Zealand Pharma.

The grant of RSUs and PSUs to Zealand Pharma’s Corporate Management below the aforementioned programs may have an estimated truthful market worth of DKK 82.2 million, based mostly on every RSU and PSU having a good worth of DKK 424.50 per share. The truthful market worth of the RSUs and PSUs is set because the closing worth of Zealand Pharma’s share on Nasdaq Copenhagen A/S the buying and selling day previous to the grant.

Every vested RSU equals one share in Zealand Pharma whereas PSUs convert right into a quantity of shares equal to between 0% to 150% of the PSUs, relying on the achievement of the efficiency targets.

For the monetary 12 months 2025, the entire aggregated worth of grants below the Lengthy-term incentive programs, together with RSUs and PSUs, can’t exceed 400% of the mounted annual wage for the CEO and 250% for different members of Government Management.

The members of the Government Management are additionally topic to a holding requirement to be met inside a interval of 5 years from the time of changing into a member of Government Management. That is to align the pursuits of the Government Management and the shareholders. The holding requirement for the members in query quantities to 200% of the mounted annual wage for the CEO, and 100% for different members of Government Management.

US Worker RSUs

As regards to the 2025 RSU grants to the US employees, the RSUs will vest yearly in equal tranches over three years (from April 19, 2025, to April 19, 2028). Every vested RSU entitles the holder to obtain one share in Zealand Pharma for gratis and topic to sure circumstances that embody the holder’s continued employment at Zealand Pharma.

The grant of RSUs to US employees below this program may have an estimated truthful market worth of DKK 7.9 million, based mostly on every RSU having a good worth of DKK 424.50 per share. The truthful market worth of the RSUs is set because the closing worth of Zealand Pharma’s share on Nasdaq Copenhagen A/S the buying and selling day previous to the grant.

Vested RSUs entitle the holder to obtain shares in Zealand Pharma for gratis, topic to the holder’s continued employment all through the vesting interval. Every vested RSU equals one share in Zealand Pharma.

RSU’s to employees in Denmark

As regards to the 2025 RSU grants to the employees in Denmark, the RSUs will vest after three years (on April 19, 2028). Every vested RSU entitles the holder to obtain one share in Zealand Pharma for gratis and topic to sure circumstances that embody the holder’s continued employment at Zealand Pharma.

The grant of RSUs to Danish employees below this program may have an estimated truthful market worth of DKK 54.6 million, based mostly on every RSU having a good worth of DKK 424.50 per share. The truthful market worth of the RSUs is set because the closing worth of Zealand Pharma’s share on Nasdaq Copenhagen A/S the buying and selling day previous to the grant.

Vested RSUs entitle the holder to obtain shares in Zealand Pharma for gratis, topic to the holder’s continued employment all through the vesting interval. Every vested RSU equals one share in Zealand Pharma.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm targeted on the invention and improvement of peptide-based medicines. Greater than 10 drug candidates invented by Zealand have superior into scientific improvement, of which two have reached the market and three candidates are in late-stage improvement. The corporate has improvement partnerships with a quantity of blue-chip pharma firms in addition to business partnerships for its marketed merchandise.

Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence in america. For extra details about Zealand’s enterprise and actions, please go to www.zealandpharma.com.

Contact
Adam Lange (Traders)
Vice President, Investor Relations
Zealand Pharma
E mail: alange@zealandpharma.com

Neshat Ahmadi (Traders)
Investor Relations Supervisor
Zealand Pharma
E mail: neahmadi@zealandpharma.com

Anna Krassowska, PhD (Traders and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
E mail: akrassowska@zealandpharma.com